Table 2 Updated results from major clinical trials with BsAbs in combinations in RR MM.

From: Bispecific antibodies in the treatment of multiple myeloma

 

MajesTEC-2 [79]

MajesTEC-2 sub-cohort [118]

MonumenTAL-2 [85]

TRIMM-2 [84]

RedirecTT-1 [41]

Agent

Teclistamab + Daratumumab + Lenalidomide

Teclistamab + Nirogacestat

Talquetamab + Pomalidomide

Talquetamab +  Daratumumab

Teclistamab + Talquetamab

No. of patients (n)

32

27

35

65

63

Patient characteristics

Median 2 (1–3) LOT,

31.3% antiCD38 Mo-B exposed

Median 4 (2–12) prior LOT

71.4% triple class refractory

21.4% penta-refractory

Median 3 prior LOT,

6.3% penta-refractory

18.3% prior CAR T

6.3% prior BsAb

Median 5 (2–16) prior LOT,

58% triple class refractory,

63% penta-refractory,

18% high risk cytogenetics,

25% with EM plasmacytomas

Median 5 (1–11) prior LOT,

78% triple class refractory,

63% penta drug exposed,

33% high-risk cytogenetics,

43% EMD

mFU in months (range)

5.78 (1–10.4)

14.7

11.4

11.5 (1.0–27.3)

14.4 (0.5–21.9)

Response

ORR: 13/13 and

VGPR: 12/13 at 0.72 mg/kg

ORR—74.1

≥CR—51.9

87% maintained response at 12 months

ORR >80%

Response as early as 1 (0.9–2.1) month

75% ORR

(66% ≥VGPR, 45% ≥CR)

All patients: 84% ORR, 34 % CR

EMD: 73% ORR, 31% CR

mDOR (months)

NA

Not reached

Not reached

NA

Not reached

mPFS (months)

NA

NA

Not reached

19.4

NA

mOS (months)

NA

NA

NA

93% at 12 months

NA

CRS

81.3 (All Gr 1, 2)

0

74.3%, 2.9% Gr 3

54.5% (all Gr 1)

81%, 3% Gr 3, no Gr 4

ICANS

Nil

1 (Gr 3)

2 (both Gr 1)

5%

1 event at dose level 3

Other adverse events

Neutropenia (Gr 3/4)—68.8%

5 Gr 5 TAE—sepsis, septic shock, COVID-19, cardiac arrest, PJP pneumonia

Grade 3/4 neutropenia 48.6%, anemia 25.7, thrombocytopenia—20%, COVID-19—14.3%

Neutropenia (38%),

Grade 3/4 26%

Neutropenia—76%, Gr 3/4 (75%)

Anemia—60%, Gr 3/4 43%

  1. mDOR median duration of response, mPFS median PFS, mOS median OS, CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, NA not available, TAE treatment-related adverse events.